447 related articles for article (PubMed ID: 24218361)
21. Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.
Krupar R; Robold K; Gaag D; Spanier G; Kreutz M; Renner K; Hellerbrand C; Hofstaedter F; Bosserhoff AK
Virchows Arch; 2014 Sep; 465(3):299-312. PubMed ID: 25027580
[TBL] [Abstract][Full Text] [Related]
22. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
23. Immune alterations and immunotherapy prospects in head and neck cancer.
Varilla V; Atienza J; Dasanu CA
Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
Hammerman PS; Hayes DN; Grandis JR
Cancer Discov; 2015 Mar; 5(3):239-44. PubMed ID: 25643909
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
26. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
27. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma.
Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K
Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792
[TBL] [Abstract][Full Text] [Related]
28. Molecular Aspects of Head and Neck Cancer Therapy.
Puram SV; Rocco JW
Hematol Oncol Clin North Am; 2015 Dec; 29(6):971-92. PubMed ID: 26568543
[TBL] [Abstract][Full Text] [Related]
29. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
Schuler PJ; Doescher JC; Laban S; Hoffmann TK
HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
[TBL] [Abstract][Full Text] [Related]
30. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Bowles DW; McDermott JD; Jimeno A
Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
[TBL] [Abstract][Full Text] [Related]
31. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies.
Badoual C; Sandoval F; Pere H; Hans S; Gey A; Merillon N; Van Ryswick C; Quintin-Colonna F; Bruneval P; Brasnu D; Fridman WH; Tartour E
Head Neck; 2010 Jul; 32(7):946-58. PubMed ID: 20191626
[TBL] [Abstract][Full Text] [Related]
32. Protective mechanisms of head and neck squamous cell carcinomas from immune assault.
Young MR
Head Neck; 2006 May; 28(5):462-70. PubMed ID: 16284974
[TBL] [Abstract][Full Text] [Related]
33. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Busch CJ; Laban S; Knecht R; Hoffmann TK
HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
[TBL] [Abstract][Full Text] [Related]
34. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
35. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
36. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
37. Novel Treatment Options in Head and Neck Cancer.
Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
[TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy Against Head and Neck Cancer Stem Cells].
Coordes A; Ochsenreither S; Qian X; Hofmann VM; Meyer JE; Karl Hoffmann T; Kaufmann AM; Albers AE
Laryngorhinootologie; 2017 Apr; 96(4):216-224. PubMed ID: 28493252
[TBL] [Abstract][Full Text] [Related]
39. The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma.
Liao P; Wang H; Tang YL; Tang YJ; Liang XH
Front Immunol; 2019; 10():2457. PubMed ID: 31708918
[TBL] [Abstract][Full Text] [Related]
40. Vaccination Expectations in HNSCC.
Syrjänen S; Rautava J
Recent Results Cancer Res; 2017; 206():257-267. PubMed ID: 27699546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
